Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.173_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Leucocyte and Eosinophil Counts Predict Progression-Free Survival in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated With PD1 Inhibition

British Journal of Haematology
Hematology
2017English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy